Blue Owl Capital Holdings LP Has $5.71 Million Stock Position in Roivant Sciences Ltd. $ROIV

Blue Owl Capital Holdings LP decreased its stake in Roivant Sciences Ltd. (NASDAQ:ROIV) by 73.4% during the 4th quarter, HoldingsChannel reports. The fund owned 263,249 shares of the company’s stock after selling 725,000 shares during the period. Roivant Sciences comprises approximately 0.4% of Blue Owl Capital Holdings LP’s portfolio, making the stock its 19th biggest holding. Blue Owl Capital Holdings LP’s holdings in Roivant Sciences were worth $5,713,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. Oregon Public Employees Retirement Fund grew its stake in shares of Roivant Sciences by 0.6% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 87,152 shares of the company’s stock worth $1,891,000 after acquiring an additional 500 shares during the last quarter. Bessemer Group Inc. grew its stake in shares of Roivant Sciences by 41.5% in the third quarter. Bessemer Group Inc. now owns 1,852 shares of the company’s stock worth $28,000 after acquiring an additional 543 shares during the last quarter. Allworth Financial LP boosted its stake in Roivant Sciences by 48.1% during the third quarter. Allworth Financial LP now owns 1,795 shares of the company’s stock worth $27,000 after buying an additional 583 shares in the last quarter. Fifth Third Bancorp boosted its stake in Roivant Sciences by 15.8% during the fourth quarter. Fifth Third Bancorp now owns 4,310 shares of the company’s stock worth $94,000 after buying an additional 588 shares in the last quarter. Finally, Utah Retirement Systems boosted its stake in Roivant Sciences by 3.0% during the third quarter. Utah Retirement Systems now owns 20,626 shares of the company’s stock worth $312,000 after buying an additional 600 shares in the last quarter. Institutional investors and hedge funds own 64.76% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on ROIV. TD Cowen lifted their price target on shares of Roivant Sciences from $38.00 to $41.00 and gave the stock a “buy” rating in a research note on Thursday. Guggenheim lifted their price target on shares of Roivant Sciences from $28.00 to $30.00 and gave the stock a “buy” rating in a research note on Monday, February 9th. Sanford C. Bernstein began coverage on shares of Roivant Sciences in a research note on Friday, March 20th. They set an “outperform” rating and a $35.00 price target on the stock. Jefferies Financial Group reiterated a “buy” rating on shares of Roivant Sciences in a research note on Tuesday, March 3rd. Finally, Leerink Partners set a $42.00 price target on shares of Roivant Sciences in a research note on Thursday. Ten analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $33.05.

Insider Buying and Selling

In other Roivant Sciences news, CEO Matthew Gline sold 289,774 shares of Roivant Sciences stock in a transaction on Thursday, April 16th. The stock was sold at an average price of $29.16, for a total transaction of $8,449,809.84. Following the completion of the transaction, the chief executive officer directly owned 16,736,116 shares of the company’s stock, valued at approximately $488,025,142.56. This trade represents a 1.70% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Melissa B. Epperly sold 41,861 shares of Roivant Sciences stock in a transaction on Monday, March 16th. The shares were sold at an average price of $28.68, for a total value of $1,200,573.48. Following the transaction, the director directly owned 15,804 shares of the company’s stock, valued at approximately $453,258.72. The trade was a 72.59% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 945,173 shares of company stock valued at $27,654,456 in the last ninety days. Insiders own 10.80% of the company’s stock.

Roivant Sciences Price Performance

ROIV opened at $29.96 on Monday. Roivant Sciences Ltd. has a fifty-two week low of $10.59 and a fifty-two week high of $32.79. The firm’s fifty day moving average price is $28.46 and its two-hundred day moving average price is $25.09. The company has a market capitalization of $21.44 billion, a P/E ratio of -49.93 and a beta of 1.14.

Roivant Sciences (NASDAQ:ROIV) last issued its quarterly earnings data on Wednesday, May 20th. The company reported $0.28 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.57. The company had revenue of $2.52 million during the quarter, compared to analysts’ expectations of $3.41 million. Roivant Sciences had a negative return on equity of 20.54% and a negative net margin of 3,629.19%.During the same period last year, the business earned ($0.29) earnings per share. On average, equities research analysts expect that Roivant Sciences Ltd. will post -1.06 EPS for the current fiscal year.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.